The current stock price of LFCR is 7.88 USD. In the past year, price increased by 21.6%.
ChartMill assigns a technical rating of 6 / 10 to LFCR. When comparing the yearly performance of all stocks, LFCR is one of the better performing stocks in the market, outperforming 82.77% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to LFCR. Both the profitability and financial health of LFCR have multiple concerns.
Over the last trailing twelve months LFCR reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS decreased by -2114.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.6% | ||
| ROE | -106.13% | ||
| Debt/Equity | 3.67 |
11 analysts have analysed LFCR and the average price target is 8.93 USD. This implies a price increase of 13.26% is expected in the next year compared to the current price of 7.88.
For the next year, analysts expect an EPS growth of 36.35% and a revenue growth 1.62% for LFCR
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.76 | 233.63B | ||
| DHR | DANAHER CORP | 30.86 | 168.08B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 188.31 | 57.22B | ||
| A | AGILENT TECHNOLOGIES INC | 26.15 | 41.37B | ||
| IQV | IQVIA HOLDINGS INC | 20.75 | 41.10B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.51 | 30.35B | ||
| WAT | WATERS CORP | 30.96 | 23.41B | ||
| ILMN | ILLUMINA INC | 33.02 | 22.00B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.89 | 19.78B | ||
| MEDP | MEDPACE HOLDINGS INC | 43.11 | 17.37B | ||
| RVTY | REVVITY INC | 23.28 | 12.64B | ||
| TEM | TEMPUS AI INC | N/A | 12.33B |
Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 406 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
LIFECORE BIOMEDICAL INC
3515 Lyman Boulevard
Chaska MINNESOTA US
Employees: 406
Phone: 19523684300
Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 406 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
The current stock price of LFCR is 7.88 USD. The price increased by 5.63% in the last trading session.
LFCR does not pay a dividend.
LFCR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
LFCR stock is listed on the Nasdaq exchange.
The Revenue of LIFECORE BIOMEDICAL INC (LFCR) is expected to grow by 1.62% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
LIFECORE BIOMEDICAL INC (LFCR) has a market capitalization of 295.26M USD. This makes LFCR a Micro Cap stock.